CpG Oligodeoxyneucleotides as TLR9 Agonists
Authors:
- 1 December 2009
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 23 (6) , 361-375
Abstract
Toll-like receptors (TLRs) are part of the innate immune system, and they belong to the pattern recognition receptors (PRR) family. The PRR family is designed to recognize and bind conserved pathogen-associated molecular patterns, which are not generated by the host and are restricted and essential to microorganisms. TLR9, which recognizes unmethylated CpG (cytosine guanosine dinucleotide), is a very promising target for therapeutic activation. Stimulation of TLR9 activates human plasmacytoid dendritic cells and B cells, and results in potent T helper-1 (Th1)-type immune responses and antitumor responses in mouse tumor models and in patients. Several pharmaceutical companies, such as Pfizer, Idera, and Dynavax, are developing CpG oligodeoxynucleotides (ODNs) for the treatment of cancer, along with other conditions, such as infections and allergy. CpG ODNs have shown promising results as vaccine adjuvants and in combination with cancer immunotherapy. Several TLR9 agonists are being developed and have entered clinical trials to evaluate their safety and efficacy for the treatment of several hematopoietic and solid tumors. In this review, we discuss the use of CpG ODNs in several phase I and II clinical trials for the treatment of NHL, renal cell carcinoma, melanoma, and non-small cell lung cancer, either alone or in combination with other agents.Keywords
This publication has 121 references indexed in Scilit:
- TLR9 traffics through the Golgi complex to localize to endolysosomes and respond to CpG DNAImmunology & Cell Biology, 2008
- The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptorNature, 2008
- TLR9 as a key receptor for the recognition of DNA☆Advanced Drug Delivery Reviews, 2008
- Significance of Toll-like Receptors Expression in Tumor Growth and Spreading: A Short ReviewCancer Microenvironment, 2008
- UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomesNature, 2008
- TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting functionEuropean Journal of Immunology, 2007
- MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer modelVaccine, 2007
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004
- TLR9 signals after translocating from the ER to CpG DNA in the lysosomeNature Immunology, 2004
- Inflammation and cancerNature, 2002